Detection of antibodies directed to the N-terminal region of GAD is dependent on assay format and contributes to differences in the specificity of GAD autoantibody assays for type 1 diabetes

Diabetes

Volumn 64, Issue 9, 2015, Pages 3239-3246

  Williams, Alistair J K ^a   Lampasona, Vito ^b   Schlosser, Michael ^c   Mueller, Patricia W ^d   Pittman, David L ^e   Winter, William E ^e   Akolkar, Beena ^f   Wyatt, Rebecca ^a   Brigatti, Cristina ^b   Krause, Stephanie ^g   Achenbach, Peter ^g  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^e UNIVERSITY OF FLORIDA   (United States)

^f NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^g TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTAMATE DECARBOXYLASE; GLUTAMATE DECARBOXYLASE 65; GLUTAMATE DECARBOXYLASE ANTIBODY; SULFUR 35; AUTOANTIBODY; EPITOPE;

AMINO TERMINAL SEQUENCE; ANTIBODY DETECTION; ANTIGEN BINDING; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOASSAY; INSULIN DEPENDENT DIABETES MELLITUS; ISOTOPE LABELING; PRIORITY JOURNAL; RADIOBINDING ASSAY; SENSITIVITY AND SPECIFICITY; STANDARDIZATION; ADOLESCENT; ADULT; CASE CONTROL STUDY; CHILD; DIABETES MELLITUS, TYPE 1; FEMALE; IMMUNOLOGY; MALE; MIDDLE AGED; RADIOASSAY; YOUNG ADULT;

ADOLESCENT; ADULT; AUTOANTIBODIES; CASE-CONTROL STUDIES; CHILD; DIABETES MELLITUS, TYPE 1; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; FEMALE; GLUTAMATE DECARBOXYLASE; HUMANS; MALE; MIDDLE AGED; RADIOLIGAND ASSAY; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 84962919786     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db14-1693     Document Type: Article

References (30)

1. Bingley PJ, Gale EA; European Nicotinamide Diabetes Intervention Trial (ENDIT) Group. Progression to type 1 diabetes in islet cell antibody-positive relatives in the European Nicotinamide Diabetes Intervention Trial: the role of additional immune, genetic and metabolic markers of risk. Diabetologia 2006;49: 881-890
2. Orban T, Sosenko JM, Cuthbertson D, et al.; Diabetes Prevention Trial-Type 1 Study Group. Pancreatic islet autoantibodies as predictors of type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 2009;32: 2269-2274
3. Haller MJ, Atkinson MA, Schatz D. Type 1 diabetes mellitus: etiology, presentation, and management. Pediatr Clin North Am 2005;52:1553-1578
4. Liu E, Eisenbarth GS. Accepting clocks that tell time poorly: fluid-phase versus standard ELISA autoantibody assays. Clin Immunol 2007;125:120-126
5. Bingley PJ, Williams A.J.K. Validation of autoantibody assays in type 1 diabetes: workshop programme. Autoimmunity 2004;37:257-260
6. Achenbach P, Schlosser M, Williams AJ, et al. Combined testing of antibody titer and affinity improves insulin autoantibody measurement: Diabetes Antibody Standardization Program. Clin Immunol 2007;122:85-90
7. Schlosser M, Mueller PW, Achenbach P, Lampasona V, Bingley PJ; Participating Laboratories. Diabetes Antibody Standardization Program: first evaluation of assays for autoantibodies to IA-2b. Diabetes Care 2011;34: 2410-2412
8. Lampasona V, Schlosser M, Mueller PW, et al. Diabetes Antibody Standardization Program: first proficiency evaluation of assays for autoantibodies to zinc transporter 8. Clin Chem 2011;57:1693-1702
9. Törn C, Mueller PW, Schlosser M, Bonifacio E, Bingley PJ; Participating Laboratories. Diabetes Antibody Standardization Program: evaluation of assays for autoantibodies to glutamic acid decarboxylase and islet antigen-2. Dia-betologia 2008;51:846-852
10. Bingley PJ, Bonifacio E, Mueller PW. Diabetes Antibody Standardization Program: first assay proficiency evaluation. Diabetes 2003;52:1128-1136
11. Bonifacio E, Yu L, Williams AK, et al. Harmonization of glutamic acid de-carboxylase and islet antigen-2 autoantibody assays for National Institute of Diabetes and Digestive and Kidney Diseases consortia. J Clin Endocrinol Metab 2010;95:3360-3367
12. Bonifacio E, Lampasona V, Bernasconi L, Ziegler AG. Maturation of the humoral autoimmune response to epitopes of GAD in preclinical childhood type 1 diabetes. Diabetes 2000;49:202-208
13. Achenbach P, Guo LH, Gick C, et al. A simplified method to assess affinity of insulin autoantibodies. Clin Immunol 2010;137:415-421
14. Curnock RM, Reed CR, Rokni S, Broadhurst JW, Bingley PJ, Williams AJ. 'Insulin autoantibody affinity measurement using a single concentration of un-labelled insulin competitor discriminates risk in relatives of patients with type 1 diabetes. Clin Exp Immunol 2012;167:67-72
15. Richter W, Shi Y, Baekkeskov S. Autoreactive epitopes defined by diabetes-associated human monoclonal antibodies are localized in the middle and C-terminal domains of the smaller form of glutamate decarboxylase. Proc Natl Acad Sci USA 1993;90:2832-2836
16. Hoppu S, Ronkainen MS, Kulmala P, Akerblom HK, Knip M; Childhood Diabetes in Finland Study Group. GAD65 antibody isotypes and epitope recognition during the prediabetic process in siblings of children with type I diabetes. Clin Exp Immunol 2004;136:120-128
17. Mayr A, Schlosser M, Grober N, et al. GAD autoantibody affinity and epitope specificity identify distinct immunization profiles in children at risk for type 1 diabetes. Diabetes 2007;56:1527-1533
18. Fenalti G, Hampe CS, Arafat Y, et al. COOH-terminal clustering of autoan-tibody and T-cell determinants on the structure of GAD65 provide insights into the molecular basis of autoreactivity. Diabetes 2008;57:1293-1301
19. Greenbaum CJ, Palmer JP, Kuglin B, Kolb H. Insulin autoantibodies measured by radioimmunoassay methodology are more related to insulin-dependent diabetes mellitus than those measured by enzyme-linked immunosorbent assay: results of the Fourth International Workshop on the Standardization of Insulin Autoantibody Measurement. J Clin Endocrinol Metab 1992;74:1040-1044
20. Hampe CS, Kockum I, Landin-Olsson M, et al. GAD65 antibody epitope patterns of type 1.5 diabetic patients are consistent with slow-onset autoimmune diabetes. Diabetes Care 2002;25:1481-1482
21. Kobayashi T, Tanaka S, Okubo M, Nakanishi K, Murase T, Lernmark A. Unique epitopes of glutamic acid decarboxylase autoantibodies in slowly progressive type 1 diabetes. J Clin Endocrinol Metab 2003;88:4768-4775
22. Butler MH, Solimena M, Dirkx R Jr, Hayday A, De Camilli P. Identification of a dominant epitope of glutamic acid decarboxylase (GAD-65) recognized by autoantibodies in stiff-man syndrome. J Exp Med 1993;178:2097-2106
23. Kim J, Namchuk M, Bugawan T, et al. Higher autoantibody levels and recognition of a linear NH2-terminal epitope in the autoantigen GAD65, distinguish stiff-man syndrome from insulin-dependent diabetes mellitus. J Exp Med 1994;180:595-606
24. Daw K, Ujihara N, Atkinson M, Powers AC. Glutamic acid decarboxylase au-toantibodies in stiff-man syndrome and insulin-dependent diabetes mellitus exhibit similarities and differences in epitope recognition. J Immunol 1996;156:818-825
25. Piquer S, Belloni C, Lampasona V, et al. Humoral autoimmune responses to glutamic acid decarboxylase have similar target epitopes and subclass that show titer-dependent disease association. Clin Immunol 2005;117:31-35
26. Brooking H, Ananieva-Jordanova R, Arnold C, et al. A sensitive non-isotopic assay for GAD65 autoantibodies. Clin Chim Acta 2003;331:55-59
27. Burbelo PD, Hirai H, Issa AT, et al. Comparison of radioimmunoprecipitation with luciferase immunoprecipitation for autoantibodies to GAD65 and IA-2beta. Diabetes Care 2010;33:754-756
28. Miao D, Guyer KM, Dong F, et al. GAD65 autoantibodies detected by electrochemiluminescence assay identify high risk for type 1 diabetes. Diabetes 2013;62:4174-4178
29. Bender C, Schlosser M, Christen U, Ziegler AG, Achenbach P. GAD auto-antibody affinity in schoolchildren from the general population. Diabetologia 2014;57:1911-1918
30. De Grijse J, Asanghanwa M, Nouthe B, et al.; Belgian Diabetes Registry. Predictive power of screening for antibodies against insulinoma-associated protein 2 beta (IA-2beta) and zinc transporter-8 to select first-degree relatives of type 1 diabetic patients with risk of rapid progression to clinical onset of the disease: implications for prevention trials. Diabetologia 2010;53:517-524